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ABSTRACT 
Objective: To investigate how comorbid conditions cluster in patients with gout in a UK 
primary care population. 
Methods: A cross-sectional study was performed using baseline data from a primary care-
based prospective observational cohort of people aged ≥ 18 years with gout. Participants with 
gout were identified through primary care medical records. Factor analysis was performed to 
obtain distinct clusters of comorbidity variables including obesity, hypertension, diabetes 
mellitus, hyperlipidaemia, coronary heart disease, heart failure, chronic kidney disease and 
cancer. Hierarchical cluster analysis of patient observations was also performed to identify 
homogenous subgroups of patients based on combinations of their comorbidities.  
Results: Four distinct comorbidity clusters (C1-C4) were identified in 1079 participants 
(mean age 65.5 years (SD 12.5); 909 (84%) male). Cluster C1 (n=197, 18%) was the oldest 
group and had the most frequent attacks of gout. 97% had chronic kidney disease. 
Participants in C2 (n=393, 36%) had isolated gout with few comorbidities but drank alcohol 
more frequently. In cluster C3 (n=296, 27%), hypertension, diabetes mellitus, 
hyperlipidaemia, coronary heart disease and/or chronic kidney disease were prevalent, and 
urate-lowering therapy was prescribed more frequently than in other clusters. All patients in 
C4 (193, 18%) had hypertension and were more likely to be obese than other clusters.  
Conclusions: Four distinct comorbidity clusters were identified. People with multiple 
comorbidities were more likely to receive allopurinol. Tailoring of treatments depending on 
cluster and comorbidities should be considered. 
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• Four distinct comorbidity clusters in gout with differing clinical phenotypes were 
identified. 
• People with gout and frequent comorbidities were most likely to receive urate-lowering 
therapy. 
• Prescription of nNon-steroidal anti-inflammatory drugs waswere commonly prescribed, 
even amongst those with gout and chronic kidney disease.   
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Introduction 
Gout is the most prevalent inflammatory arthritis, affecting 2.5% of adults in the UK [1]. It 
has complex associations with comorbidity with some medical conditions predisposing to 
gout whereas gout is itself a risk factor for other comorbidities. For example, obesity, 
hypertension, and obstructive sleep apnoea all predispose to the development of gout [2-4], 
whereas gout is an independent risk factor for incident cardiovascular disease, nephrolithiasis 
and erectile dysfunction [4-7].  Chronic kidney disease (CKD) is a risk factor for gout which 
can then in turn lead to deterioration of renal function and worsening CKD [4,8,9]. Common 
treatments for hypertension, cardiac and renal disease, particularly diuretics, are also risk 
factors for incident hyperuricaemia and gout [10]. Furthermore, the management of gout is 
often more complex in the presence of comorbidity, presenting a significant therapeutic 
challenge. 
Most existing studies have considered the epidemiological relationships between gout 
and single comorbid conditions. Few have taken into account the frequent co-occurrence of 
multiple comorbidities although metabolic syndrome is three times more common in people 
with gout than age- and gender-matched controls without gout [11]. A recent French study 
was the first to examine how different comorbidities cluster together in people with gout, 
identifying five distinct comorbidity clusters ranging from a cluster characterised by people 
with isolated gout and few comorbidities to one with a very high prevalence of cardiac and 
renal disease [12].  
The aims of this observational study therefore were to explore whether such 
comorbidity clusters are generalizable to people with gout in other settings, by examining the 
existence of comorbidity clusters among people with gout recruited from primary care in the 
UK, and to compare gout characteristics, comorbidities and prescribed medication between 
any clusters identified. 
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Methods 
The study used baseline data from a primary care-based prospective cohort study of adults 
aged 18 years and over with gout, registered with 20 general practices across the West 
Midlands, UK [13]. Ethical approval was obtained from North West – Liverpool East 
Research Ethics Committee (REC reference number: 12/NW/0297).  Full details of the study 
may be found elsewhere [13]. In summary, participants with gout were identified through 
electronic primary care records of participating general practices using specific Read codes 
for gout, or a prescription of allopurinol or colchicine in the preceding two years. Eligible 
patients were mailed a self-report questionnaire that requested information about different 
aspects of gout and their general health. Specific questions about gout included age at 
diagnosis, number of attacks experienced in the preceding 12 months, and history of gout 
attacks affecting more than one joint (oligo/polyarticular gout attacks). The questionnaire also 
asked about alcohol consumption and self-reported height and weight, from which BMI was 
calculated. Obesity was defined as BMI≥30 kg/m2. Participants were asked to provide 
consent for the research team to review their medical records. Baseline responders who 
consented to medical record review formed the analysis sample for this study. 
Medical records were reviewed for the preceding two years for primary care 
consultations, medications and comorbidities. Hypertension, diabetes mellitus, 
hyperlipidaemia, liver disorders, coronary heart disease (CHD), heart failure, cancer and the 
presence of renal calculi and tophi were ascertained via Read codes. Estimated glomerular 
filtration rate (eGFR) was also extracted from the medical record with CKD stage≥3 defined 
as eGFR<60ml/min and sub-divided into stage 3 (eGFR 30-59ml/min) and stage 4/5 
(eGFR<30ml/min). The metabolic syndrome was defined as the presence of BMI>30kg/m2 
and at least two of the following: hyperlipidaemia, currently taking lipid-lowering agents, 
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diabetes mellitus, or hypertension [14]. The total number of primary care consultations during 
the two years prior to study entry was calculated.  
Using relevant British National Formulary codes, prescriptions for non-steroidal anti-
inflammatory drugs (NSAIDs), prednisolone, colchicine, allopurinol, aspirin, lipid-lowering 
drugs (other than fenofibrate), fenofibrate, diuretics, losartan and anti-hypertensive 
medications, were identified in the medical records of consenting participants during the 
preceding two years. Only five participants received non-allopurinol urate-lowering therapy 
hence only use of allopurinol was considered. 
Lists of all Read codes used may be found in the morbidity section of the medical 
record data research repository at www.keele.ac.uk/mrr. 
 
Statistical analysis 
Age and BMI were summarised via mean and standard deviation, and gout duration and total 
number of primary care consultations by median and interquartile range (IQR), and 
categorical variables via frequencies and percentages. Clustering of comorbidities was first 
examined, aiming to establish any underlying factor structure among the comorbid 
conditions. For this purpose, principal components analysis was performed to extract factors 
using oblique rotation (direct oblimin, which assumes correlated factors), with eigenvalue > 1 
criterion. A particular comorbidity loaded a factor if the value of the loading was highest for 
that factor. Comorbidities considered were:  obesity, hypertension, diabetes mellitus, 
hyperlipidaemia, CHD, heart failure, CKD and cancer. Only two patients had a record of liver 
disorders hence this comorbidity was not considered in cluster analyses. Patients for whom 
BMI was missing were excluded from the main analysis, however subsequently, sensitivity of 
the findings to include missing BMI as a separate category was assessed. Comorbidities’ 
correlation matrix was initially visually inspected for extreme multicollinearity. Subsequently 
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the Kaiser-Meyer-Olkin (KMO) test was performed to assess more formally the adequacy of 
data for factor analysis, taking test values of greater than 0.5 as acceptable; furthermore 
significance of Bartlett’s measure, testing the null hypothesis that the correlation matrix is an 
identity matrix, was required [15]. As a sensitivity analysis, orthogonal rotation Varimax, 
which does not assume correlated factors, was used too. Next, agglomerative hierarchical 
cluster analysis, using Ward’s minimum variance method [16] was performed to place 
patients into homogeneous groups based on combinations of their comorbidities, considering 
the same set as in the factor analysis. The algorithm started with each patient in their own 
cluster; at each subsequent step, clusters were combined in a way that minimized within 
cluster sum of squares and the process was repeated until one single cluster was obtained.  
For diagnoses of comorbidities and indication of use of different drugs, it was 
assumed that those without a record of the relevant Read code or BNF code did not have the 
corresponding comorbidity or drug prescribed respectively.  
Analyses were performed in SPSS for Windows.[17] 
 
RESULTS 
Survey response figures have been reported in detail elsewhere [18]. In summary, the 
baseline survey population consisted of 1805 patients, of whom nine were excluded during 
the mailing process due to death or serious health reasons. Of the remaining 1796 patients, 
1184 (66%) responded to the baseline survey. Responders tended to be older, more likely to 
be male and live in less deprived areas compared than non-responders [18]. 1079 (91%) of 
responders consented to review of their medical records and formed the analysis sample.  
Characteristics of the sample and distribution of comorbidities and medication use are 
presented in tables 1 and 2.  
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Participants were predominantly male (84%) and mean age was 65.5 ± 12.5 years. 
Mean age at gout diagnosis was 53.3 ± 15.8 years. 666 (65%) participants reported having at 
least one gout attack in the last 12 months and 399 (39%) had a history of oligo/polyarticular 
attacks. The median number of primary care consultations in the preceding six months was 
14 (interquartile range 4-28). Daily consumption of alcoholic drinks was reported by 259 
(24%). Comorbidities were common, particularly obesity, hypertension and CKD.   During 
the preceding two years, prescriptions for NSAIDs, allopurinol, and non-losartan anti-
hypertensive medications were received by 60% of participants, while 58% received a 
prescription for lipid-lowering drugs and 27% for diuretics. Colchicine was prescribed for 
32%.   
                  
Clustering of comorbidities 
There were no extreme correlations >0.9 and no comorbidity that was completely 
uncorrelated with the other comorbidities. The KMO statistic was 0.587 and Bartlett’s test 
was significant (p<0.001), implying that factor analysis was appropriate. Three factors were 
extracted accounting for 54.7% of the variance (table 3). These were: F1 diabetes, 
hyperlipidaemia and coronary heart disease, F2 obesity and heart failure, F3 hypertension and 
CKD. Addition of cancer reduced the total variance explained to 48.6% hence cancer was not 
included. Identical results were obtained when using orthogonal rather than oblique factor 
rotation (data not shown).  
 
Clustering of patients 
The same set of variables was used as in the factor analysis. Four comorbidity clusters (C1-
C4) were identified and their characteristics are presented in tables 1 and 2.   
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Cluster C1 (n=197, 18%) had the lowest proportion of males (69%) and highest mean age 
and mean age at gout diagnosis (73 years, 63 years respectively) compared to other clusters. 
CKD was very common (97%; stage 3 79%; stage 4/5 18%) and almost half had 
hypertension; other comorbidities were infrequent. Furthermore, patients in C1 reported more 
gout attacks in the last 12 months and were more likely to be prescribed prednisolone, 
colchicine and diuretics compared to patients in other clusters. Almost half (49%), were 
prescribed NSAIDs. Participants in C2 (n=393, 36%) had the lowest mean age, lowest mean 
age at gout diagnosis, lowest mean BMI, very infrequent comorbidities, and lowest median 
number of consultations within two years prior to study entry compared to other clusters, but 
drank alcoholic drinks more frequently and were more likely to be prescribed NSAIDs. Most 
comorbidities were prevalent in C3 (296, 27%): coronary heart disease (52%), diabetes 
mellitus (50%), hypertension (49%), CKD (43%; stage 3 36%; stage 4/5 6%), 
hyperlipidaemia (36%) and metabolic syndrome (31%) were common. Over 80% received 
lipid-lowering drugs and antihypertensive medications, one-half were prescribed aspirin, and 
one-third diuretics. Participants in C3 had the longest duration of gout (median 11, IQR 4-
22), had the highest median number of primary care consultations (23, IQR 14-39) and were 
more likely to be prescribed allopurinol compared to patients in other clusters. All patients in 
C4 (193, 18%) had hypertension and 44% were classed as obese, a higher proportion than in 
other clusters. Antihypertensive medications were prescribed for 85%. 
 
DISCUSSION 
This is one of the first studies to examine clustering of comorbidities in patients with gout. In 
our sample of patients with gout recruited from UK primary care, we identified four distinct 
comorbidity clusters (C1-C4). C1 comprised the oldest participants who reported the most 
frequent gout attacks. Despite almost all participants having CKD and prescription of 
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NSAIDs being less common in this cluster than others, almost one-half of participants were 
still prescribed an NSAID. C2 consisted of younger participants who had isolated gout with 
few comorbidities. In C3, hypertension, hyperlipidaemia, diabetes mellitus, CKD and/or 
coronary heart disease were prevalent. These participants had the longest duration of gout and 
were the most likely to receive ULT. All participants in C4 had hypertension and almost a 
half were obese. In clusters 1 and 3, most participants with CKD had stage 3 disease. 
There has only been one previous study looking at clustering of comorbidities in gout, 
in which five clusters were identified (c1 isolated gout with few comorbidities; c2 obesity 
with hypertension; c3 mostly diabetic; c4 predominant dyslipidaemia; and c5 cardiovascular 
disease and renal failure) [12]. Although our analysis found one cluster fewer than this study, 
there are some similarities between the findings. Both studies identified an isolated cluster 
with few comorbidities and a more severe cluster with highly prevalent CKD. The isolated 
gout cluster had few recognised risk factors for gout, other than a third being obese and a 
third consuming at least moderate volumes of beer per week, raising the possibility that 
genetic factors could be of particular relevance in this cluster. Unfortunately, we did not ask 
about family history of gout so could not explore this further. Although both studies 
ascertained a cluster with prevalent obesity and hypertension, in the study by Richette et al 
[12] other comorbidities were common in this cluster in contrast to our study. Their 
remaining clusters comprised different combinations of multiple traditional cardiovascular 
risk factors whereas we could only identify a single additional cluster. These differences may 
reflect our smaller sample size or that our participants were recruited exclusively from 
primary care. Richette et al recruited from both primary and secondary care and hence may 
have recruited a more severely affected cohort, as suggested by the considerably higher 
prevalences of tophi, renal calculi and all comorbidities (except for CHD and renal failure) 
than seen in our sample. In our study, the isolated gout cluster with few comorbidities was the 
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largest (36%) in contrast to Richette et al where it comprised only 12% of the study sample. 
A further discrepancy between our study and that of Richette et al is that liver disorders were 
very infrequent in our population. This could reflect either differing methods of 
ascertainment or differences in the severity of the two cohorts. Our study also makes 
important observations about the treatment of gout. Participants with frequent comorbidities 
(C3) were more likely to receive ULT than those in other clusters, as has been shown in 
several other studies [19-21]. In contrast, people with CKD (C1) had the most frequent 
attacks of gout yet the lowest rates of ULT prescription, highlighting the challenges of 
treating gout in CKD. It is also noteworthy that 49% of participants in C1 were prescribed 
NSAIDs despite CKD being a contra-indication to NSAID use, risking further deterioration 
in renal function. 
Previous research has suggested that lipid levels play a central role in determining 
serum urate levels. In a study of obese patients undergoing bariatric surgery, pre-operative 
serum urate levels correlated with triglyceride levels and BMI, and post-operatively the 
decrease in serum urate correlated with reductions in triglyceride levels and BMI but not 
xanthine oxidase activity or insulin resistance [22]. The authors postulated that reductions in 
serum urate levels associated with weight loss might be partly attributable to increased renal 
urate excretion secondary to lowering of triglyceride levels. It is interesting therefore that in 
our study the proportion with obesity was similar between the four clusters (range 29-44%) 
but hyperlipidaemia was seen only in C3 where other comorbidities were also commonplace. 
Low high-density lipoprotein and high total cholesterol levels are also associated with failure 
to reach a target serum urate level in patients receiving ULT [23]. Unfortunately, serum urate 
levels are often infrequently measured in clinical practice in primary care and hence we were 
unable to make meaningful comparisons of serum urate levels between the clusters as serum 
urate levels had been checked in only a minority of participants (n=461).  CKD and diuretic 
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use are also important risk factors for hyperuricaemia and gout. In both clusters with 
prevalent CKD (C1 and C3), use of diuretics was frequent as well as other medications which 
may predispose to hyperuricaemia and gout particularly beta-blockers and angiotensin-
converting enzyme inhibitors [24]. Hence, multiple factors may be contributing to 
hyperuricaemia in these clusters. 
The strengths of this study include the statistical methodology and the primary care 
setting ensuring relevance of our findings to the majority of people with gout who are 
managed exclusively in primary care. The diagnosis of gout was based on diagnosis by a GP, 
risking misclassification bias, however our previous studies have shown that this does not 
seem to occur frequently [252,263]. Misclassification of comorbidities is also possible, 
however, this is less likely to be significant as comorbidities were ascertained from 
participants’ medical records rather than relying on participant self-report.  
Our findings support the generalisability of the comorbidity clusters in gout 
previously reported by Richette et al [12]. Further research is needed to explore 
pathophysiological processes in these clusters such as the roles of genetic factors and 
dyslipidaemia, and the relative contributions of renal disease and medicationshow these 
clusters relate to pathophysiological processes. Prospective studies should investigate the 
influence of clustering of comorbidities on the prognosis and natural history of gout and the 
risk of developing incident gout, as well as how clustering changes with time and whether 
participants move between clusters. Whilst people with multiple comorbidities seem more 
likely to receive ULT, better efforts are required to offer treatment to those with isolated gout 
and to optimise treatment in people with CKD who appear to have more severe gout in this 
study. 
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Table 1: Demographic, gout, and healthcare use and alcohol consumption characteristics of the whole cohort providing consent to 
medical record review (n=1079) and the four comorbidity clusters  
 
 All (n=1079) Cluster 1 (n=197) Cluster 2 (n=393) Cluster 3 (n=296) Cluster 4 (n=193) 
Demographics      
Male gender 909 (84) 135 (69) 350 (89) 256 (86) 168 (87) 
Age, mean years (SD) 65.5 (12.5) 73.2 (11.0) 58.3 (12.3) 69.9 (9.1) 65.4 (10.6) 
BMI, mean (SD)    29.2 (5.1) 28.9 (5.3) 28.6 (4.7) 29.1 (5.0) 30.4 (5.5) 
History of gout      
Age at diagnosis, mean (SD) 53.3 (15.8) 63.4 (16.6) 47.0 (13.6) 55.4 (15.2) 53.3 (14.4) 
Duration of gout, median (IQR) 8.0 (2-18) 4 (2-14) 7 (2-18) 11 (4-22) 9 (3-20) 
Number of gout attacks in last 
12 months      0 
                     1-2 
                     ≥3 
 
361 (35) 
381 (37) 
285 (28) 
 
53 (30) 
69 (38) 
58 (32) 
 
131 (34) 
146 (39) 
102 (27) 
 
107 (38) 
96 (34) 
77 (28) 
 
70 (37) 
70 (37) 
48 (26) 
Oligo/polyarticular attacks                 399 (39) 68 (35) 145 (37) 114 (39) 72 (37) 
Tophi 25 (2) 7 (4) 6 (2) 2 (1) 1 (1) 
Renal calculi 9 (1) 0 (0) 6 (2) 2 (1) 1 (1) 
Healthcare use 
Total number of consultations, 
Median (IQR) 
 
 
14 (4-28) 
 
 
19 (1-35) 
   
 
7 (1-15) 
 
 
23 (14-39) 
 
 
14 (6-23) 
Alcohol consumption      
Daily 259 (24) 42 (22) 102 (26) 65 (22) 50 (26) 
Weekly 460 (43) 70 (36) 186 (48) 118 (40) 86 (45) 
Monthly 106 (10) 19 (10) 33 (8) 32 (11) 22 (11) 
Never/special occasions 242 (23) 62 (32) 68 (18) 78 (27) 34 (18) 
>4 glasses wine per week 69 (6)  10 (5) 33 (8) 13 (4) 13 (7) 
>7 pints of beer per week 266 (25)  19 (10) 132 (34) 49 (17) 66 (34) 
>14 shots of spirits per week 29 (3) 6 (3) 6 (2) 8 (3) 9 (5) 
Values are n (%) unless otherwise stated. SD standard deviation; IQR interquartile range 
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Table 2: Comorbidities and medications use among the whole cohort providing consent to medical record review (n=1079) and the four 
clusters   
 
 All (n=1079) Cluster 1 
(n=197) 
Cluster 2 
(n=393) 
Cluster 3 
(n=296) 
Cluster 4 
(n=193) 
Comorbidity      
Obesitya 358 (35) 57 (29) 116 (30) 100 (34) 85 (44) 
Hypertension 432 (40) 95 (48) 0 (0) 144 (49) 193 (100) 
Diabetes mellitus 175 (16) 1 (1) 0 (0) 147 (50) 27 (14) 
Hyperlipidaemia 106 (10) 0 (0) 0(0) 106 (36) 0(0) 
Metabolic syndromeb 181 (17) 31 (16) 0 (0) 91 (31) 59 (31) 
Liver disorders 2 (<0.5) 0 (0) 1 (<0.5) 1 (<0.5) 0 (0) 
Coronary heart disease 157 (15) 4 (2) 0 (0) 153 (52) 0 (0) 
Heart failure 27 (3) 13 (7) 0 (0) 14 (5) 0 (0) 
Chronic kidney disease stage ≥3 (eGFR<60ml/min) 318 (30) 192 (97) 0 (0) 126 (43) 0 (0) 
 Stage 3 (eGFR 30-59ml/min) 263 (25) 156 (79) 0 (0) 107 (36) 0 (0) 
 Stage 4/5 (eGFR<30ml/min) 55 (5) 36 (18) 0 (0) 19 (6) 0(0) 
Cancer 34 (3) 9 (5) 10 (3) 13 (4) 2 (1) 
Medications      
NSAIDs 634 (60) 96 (49) 250 (64) 172 (58) 116 (60) 
Prednisolone 152 (14) 40 (20) 47 (12) 51 (17) 14 (7) 
Colchicine 345 (32) 84 (43) 113 (29) 96 (32) 52 (27) 
Allopurinol 646 (60) 110 (56) 218 (55) 202 (68) 116 (60) 
Aspirin 282 (26) 63 (32) 36 (9) 152 (51) 31 (16) 
Lipid-lowering drugsc 628 (58) 134 (68) 133 (34) 256 (86) 105 (54) 
Diuretics 286 (27) 97 (49) 28 (7) 110 (37) 51 (26) 
Losartan 55 (5) 13 (7) 5 (1) 21 (7) 16 (8) 
Non-losartan ARB 118 (11) 30 (15) 8 (2) 56 (19) 24 (12) 
Beta-blockers 297 (28) 79 (40) 34 (9) 138 (47) 46 (24) 
ACE-inhibitors 413 (38) 109 (55) 46 (12) 154 (52) 104 (54) 
Calcium channel blockers 276 (26) 69 (35) 26 (7) 93 (31) 88 (46) 
Any non-losartan anti-hypertensive drugs 649 (60) 156 (79) 77 (20) 252 (85) 164 (85) 
[19] 
 
Values are n (%). adefined as body mass index > ≥30kg/m2;  b Defined as body mass index > 30kg/m2 AND two of: hyperlipidaemia/lipid lowering therapy, 
hypertension or diabetes; c Other than fenofibrate; d Include non-losartan ARB, Beta-blockers, ACE-inhibitors, calcium channel blockers. 
  
[20] 
 
Table 3: Exploratory factor analysis 
 
 Factor 
Comorbidity 1 2 3 
Obesity 0.118 0.771 0.128 
Hypertension 0.068 0.294 0.680 
Diabetes 0.471 0.290 0.403 
Hyperlipidaemia 0.759 0.087 -0.126 
Coronary heart disease 0.708 -0.188 0.244 
Heart failure 0.350 -0.491 0.270 
Chronic kidney disease 0.114 -0.320 0.725 
Factors with eigenvalue >1 are extracted; comorbidity’s highest loading is highlighted 
 
